[Effects of long-term treatment with L-carnitine on dyslipemia in hemodialysis patients].
The effect of long-term intravenous administration of L-carnitine on the lipid pattern of 18 patients on intermittent haemodialysis has been evaluated. Serum levels of carnitine were assayed at the beginning and after 4 months of treatment: no significant change was observed. At the end of our investigation, we found a significant reduction of HDL-cholesterol and a significant increase of triglyceride levels, compared with basal values. On the contrary cholesterol levels did not change. Five of the patients though behaved as responders to the treatment: their triglyceride levels decrease while their carnitine values rose significantly. The Authors discuss the therapeutic importance of L-carnitine and its possible influence on dyslipaemia of uremic haemodialysed patients.
D002331:Carnitine / Q000097:blood / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000097:blood; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D006435:Renal Dialysis / Q000009:adverse effects*; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008055:Lipids; D014280:Triglycerides; D002331:Carnitine
Effetti della terapia a lungo termine con L-carnitina sulla dislipemia dei pazienti in emodialisi.